Dexcom Inc Stock Last Dividend Paid
DXCM Stock | USD 137.87 3.87 2.89% |
DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.
DexCom | Last Dividend Paid |
DexCom Inc Company Last Dividend Paid Analysis
DexCom's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
DexCom Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for DexCom is extremely important. It helps to project a fair market value of DexCom Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since DexCom's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DexCom's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DexCom's interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition |
DexCom Additional Paid In Capital
Additional Paid In Capital |
|
Based on the recorded statements, DexCom Inc has a Last Dividend Paid of 0.0. This indicator is about the same for the Health Care Equipment & Supplies average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
All Next | Launch Module |
DexCom ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
DexCom Fundamentals
Return On Equity | 0.26 | ||||
Return On Asset | 0.0641 | ||||
Profit Margin | 0.15 % | ||||
Operating Margin | 0.21 % | ||||
Current Valuation | 50.57 B | ||||
Shares Outstanding | 385.52 M | ||||
Shares Owned By Insiders | 0.40 % | ||||
Shares Owned By Institutions | 99.60 % | ||||
Number Of Shares Shorted | 14.57 M | ||||
Price To Earning | 245.31 X | ||||
Price To Book | 25.38 X | ||||
Price To Sales | 14.49 X | ||||
Revenue | 3.62 B | ||||
Gross Profit | 1.88 B | ||||
EBITDA | 916.7 M | ||||
Net Income | 541.5 M | ||||
Cash And Equivalents | 2.37 B | ||||
Cash Per Share | 6.14 X | ||||
Total Debt | 2.59 B | ||||
Debt To Equity | 1.17 % | ||||
Current Ratio | 3.77 X | ||||
Book Value Per Share | 5.37 X | ||||
Cash Flow From Operations | 748.5 M | ||||
Short Ratio | 4.32 X | ||||
Earnings Per Share | 1.30 X | ||||
Price To Earnings To Growth | 2.53 X | ||||
Target Price | 151.32 | ||||
Number Of Employees | 9.5 K | ||||
Beta | 1.21 | ||||
Market Capitalization | 51.66 B | ||||
Total Asset | 6.26 B | ||||
Retained Earnings | 1.02 B | ||||
Working Capital | 2.87 B | ||||
Current Asset | 231.3 M | ||||
Current Liabilities | 66.9 M | ||||
Net Asset | 6.26 B |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving together with DexCom Stock
0.67 | NXL | Nexalin Technology | PairCorr |
Moving against DexCom Stock
0.77 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
0.74 | NUWE | Nuwellis Financial Report 14th of May 2024 | PairCorr |
0.73 | UNH | UnitedHealth Group Financial Report 12th of July 2024 | PairCorr |
0.73 | NAOV | NanoVibronix | PairCorr |
0.66 | HSTM | HealthStream | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out DexCom Piotroski F Score and DexCom Altman Z Score analysis. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.3 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.